| Project/Area Number |
24590348
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General medical chemistry
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
TAKEI YOSHIFUMI 名古屋大学, 医学(系)研究科(研究院), 准教授 (70362233)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KADOMATSU Kenji 名古屋大学, 大学院医学系研究科, 教授 (80204519)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 核酸医薬 / siRNA / drug delivery / アテロコラーゲン / 癌治療 / 炎症治療 / コラーゲン受容体 / MCP-1 / ドラッグデリバリー / 細胞特異的 / マクロファージ |
|---|
| Outline of Final Research Achievements |
Successful short interfering RNA (siRNA)-based therapy for various diseases depends on functional siRNA delivery specific to disease-responsible cells in vivo. We have shown siRNA/atelocollagen complex was specifically delivered into inflammatory macrophages in inflammatory sites, or tumor cells in tumor tissues in vivo. Thus, we aimed the molecular mechanism to explain the specific delivery. According to comprehensive gene expression array analysis, we found many upregulated genes, which conserve collagen-binding properties, in inflammatory macrophages and tumor cells. Among them, we discovered that CD280, a transmembrane-type collagen receptor, can play a critical role in such specific uptake of siRNA/atelocollagen complex into inflammatory macrophages and tumor cells.
|
